How [CLIENT_TYPE] Achieved [RESULT] with NABP [PROGRAM_TYPE] Accreditation — IHS Case Study

Client Overview

Organization Type

[ORG_TYPE] — e.g., independent specialty pharmacy / regional wholesale distributor / health-system outpatient pharmacy

Size

[SIZE] — e.g., single location / [X] dispensing locations / [X] distribution facilities

Location

[STATE/REGION]

Accreditation Sought

[NABP_PROGRAM] — e.g., NABP Drug Distributor Accreditation (DDA) / NABP Specialty Pharmacy Accreditation / Dual NABP + URAC

Engagement Start

[MONTH, YEAR]

Accreditation Awarded

[MONTH, YEAR]

The Challenge

[CLIENT_TYPE] — a [SIZE] [ORG_TYPE] in [STATE] — needed [NABP_PROGRAM] accreditation to [BUSINESS_DRIVER]. [Add 1–2 sentences of context: state mandate, PBM contract deadline, expansion plan, acquisition requirement, etc.]

They came to IHS [describe how/why they engaged IHS — referral, prior relationship, specific gap they recognized].

Key Obstacles at Engagement Start

• [OBSTACLE_1] — e.g., SOP manuals had not been updated since [YEAR] and did not reflect current USP 795/797 requirements
• [OBSTACLE_2] — e.g., no designated person for compounding had been named in writing
• [OBSTACLE_3] — e.g., temperature monitoring system had [X]-hour gaps in logging continuity
• [OBSTACLE_4] — e.g., patient profiles were missing diagnosis codes and therapeutic goals for [X]% of active patients
• [OBSTACLE_5] — e.g., carrier vetting procedures did not document criminal background check or toxicology screening verification

The IHS Approach

IHS used its standard four-phase NABP engagement structure, adapted to [CLIENT_TYPE]'s specific documentation maturity and timeline constraints.

Phase 1: Gap Analysis

Duration: [DURATION] — e.g., 3 weeks

IHS conducted a comprehensive gap analysis mapping [CLIENT_TYPE]'s existing operations, policies, personnel files, and facility conditions against [NABP_PROGRAM] standards. The analysis identified [X] distinct deficiencies across [Y] standard sections.

Key findings: [LIST_1–3_MAJOR_GAP_FINDINGS]

IHS delivered a prioritized remediation roadmap with assigned owners, documentation requirements, and sequencing recommendations — distinguishing items that needed to be resolved before NABP application submission from items that could be addressed in parallel with the desk review process.

Phase 2: Documentation Development

Duration: [DURATION] — e.g., 8 weeks

IHS [authored / revised] [X] SOP documents covering [LIST_AREAS — e.g., drug procurement, controlled substance security, temperature monitoring protocols, carrier vetting procedures, patient profile standards, DUR system documentation].

[Describe any notable documentation challenges and how they were resolved — e.g., thermal mapping study commissioned, DEA perpetual inventory system implemented, patient profile template redesigned, welcome kit tracking workflow built.]

[CLIENT_TYPE]'s [ROLE — e.g., Director of Pharmacy] served as the internal point of contact, with IHS managing the document development calendar and NABP submission queue.

Phase 3: Mock Survey

Duration: [DURATION] — e.g., 1 day on-site + 1 week remediation

IHS conducted a full mock survey [X] weeks before the scheduled NABP on-site visit. The mock survey covered [LIST: facility walkthrough areas, document categories reviewed, staff interview topics].

The mock survey identified [X] remaining deficiencies that the desk review process had not surfaced: [LIST_FINDINGS]. All [X] findings were remediated before the official NABP survey date.

[Optional: describe staff preparation element — e.g., IHS conducted a 2-hour staff briefing on surveyor interview protocols, covering how to respond to questions about DUR scope, patient education documentation, and SOP familiarity.]

Phase 4: On-Site Survey and Post-Survey Support

Duration: [DURATION] — e.g., 2-day NABP survey + [X] weeks post-survey

The official NABP [survey type — e.g., Supply Chain Inspection / Specialty Pharmacy on-site survey] was conducted on [MONTH, YEAR]. [Describe how it went — e.g., the survey proceeded without significant incident / the surveyor identified [X] findings in the post-survey letter].

[If corrective action was needed:] NABP issued a post-survey letter citing [X] findings. IHS authored corrective action plans for each cited deficiency, implementing [describe remediation] within [X] weeks of the post-survey letter.

[If clean survey:] NABP issued no material findings. Three-year accreditation was awarded [X] weeks after the survey date.

Total Engagement

Total Duration

[TOTAL_DURATION] — e.g., 7 months from engagement start to accreditation award

Industry Average

6–9 months (source: NABP)

IHS Documents Authored or Revised

[X] SOP documents, [X] policy frameworks, [X] supporting templates

Mock Survey Deficiencies Identified and Remediated Pre-Survey

[X]

Post-Survey Corrective Action Items

[X] — or "None" if clean survey

The Results

[CLIENT_TYPE] received [NABP_PROGRAM] accreditation in [MONTH, YEAR] — [ahead of / within / at the outer edge of] the industry average 6–9 month timeline.

• [RESULT_1] — e.g., Achieved NABP DDA accreditation in [X] months, [X weeks ahead of] the state mandate deadline
• [RESULT_2] — e.g., Gained participation in the Optum Rx Specialty Pharmacy Network within [X] weeks of accreditation award
• [RESULT_3] — e.g., Zero post-survey corrective action findings — first-attempt clean survey
• [RESULT_4] — e.g., Pharmacy Director reported [X]% reduction in accreditation-related administrative time compared to prior cycle
• [RESULT_5] — e.g., Dual NABP + URAC accreditation achieved within [X] months of each other using shared documentation framework

"[CLIENT_QUOTE]"

— [NAME], [TITLE], [ORGANIZATION] (with permission)

Timeline: Actual vs. Industry Average

Key Takeaways

1. [TAKEAWAY_1_HEADLINE]

   [TAKEAWAY_1_DETAIL] — e.g., Front-loading the gap analysis before NABP application submission prevented the most common timeline extender: discovering documentation gaps after the desk review clock has started. Every deficiency identified in IHS's gap analysis was remediated on our timeline, not NABP's.

2. [TAKEAWAY_2_HEADLINE]

   [TAKEAWAY_2_DETAIL] — e.g., The mock survey surfaced [X] deficiencies that the document review had missed — primarily in the facility operations and staff interview components. None of these appeared in the post-survey letter because they were remediated before the NABP surveyor arrived.

3. [TAKEAWAY_3_HEADLINE]

   [TAKEAWAY_3_DETAIL] — e.g., Carrier vetting documentation is consistently the most underestimated requirement for wholesale distributors. NABP requires written verification that contracted carriers conduct criminal background checks and random toxicology screenings — most distributors have never operationalized this as a documented vendor qualification process. Building this workflow required [describe approach].

About IHS

Integral Healthcare Solutions is the only URAC-certified accreditation consulting firm in the United States. IHS provides consulting services for NABP, URAC, ACHC, and Joint Commission pharmacy accreditation programs — the only firm with active expertise across all four bodies. Principal Thomas G. Goddard, JD, PhD leads all pharmacy accreditation engagements.

Start Your NABP Accreditation Engagement

Every IHS engagement begins with a gap analysis that tells you exactly where you stand against NABP standards before you submit a single document. No obligation, no timeline commitment — just a clear picture of what accreditation will require and what IHS will do to get you there.